• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int Immunopharmacol . Impact of asthma on COVID-19 mortality in the United States: Evidence based on a meta-analysis

tetano

Editor, Senior Moderator
Int Immunopharmacol


. 2021 Nov 22;108390.
doi: 10.1016/j.intimp.2021.108390. Online ahead of print.
Impact of asthma on COVID-19 mortality in the United States: Evidence based on a meta-analysis


Xueya Han[SUP] 1 [/SUP], Jie Xu[SUP] 1 [/SUP], Hongjie Hou[SUP] 1 [/SUP], Haiyan Yang[SUP] 2 [/SUP], Yadong Wang[SUP] 3 [/SUP]



Affiliations

Abstract

Objective: The aim of this study was to investigate the impact of asthma on the risk for mortality among coronavirus disease 2019 (COVID-19) patients in the United States by a quantitative meta-analysis.
Methods: A random-effects model was used to estimate the pooled odds ratio (OR) with corresponding 95% confidence interval (CI). I[SUP]2[/SUP] statistic, sensitivity analysis, Begg's test, meta-regression and subgroup analyses were also performed.
Results: The data based on 56 studies with 426,261 COVID-19 patients showed that there was a statistically significant association between pre-existing asthma and the reduced risk for COVID-19 mortality in the United States (OR: 0.82, 95% CI: 0.74-0.91). Subgroup analyses by age, male proportion, sample size, study design and setting demonstrated that pre-existing asthma was associated with a significantly reduced risk for COVID-19 mortality among studies with age ≥ 60 years old (OR: 0.79, 95% CI: 0.72-0.87), male proportion ≥ 55% (OR: 0.79, 95% CI: 0.72-0.87), male proportion < 55% (OR: 0.81, 95% CI: 0.69-0.95), sample sizes ≥ 700 cases (OR: 0.80, 95% CI: 0.71-0.91), retrospective study/case series (OR: 0.82, 95% CI: 0.75-0.89), prospective study (OR: 0.83, 95% CI: 0.70-0.98) and hospitalized patients (OR: 0.82, 95% CI: 0.74-0.91). Meta-regression did reveal none of factors mentioned above were possible reasons of heterogeneity. Sensitivity analysis indicated the robustness of our findings. No publication bias was detected in Begg's test (P = 0.4538).
Conclusion: Our findings demonstrated pre-existing asthma was significantly associated with a reduced risk for COVID-19 mortality in the United States.

Keywords: Asthma; COVID-19; Meta-analysis; Mortality; USA.
 
Back
Top Bottom